Subscription Required

Only paid subscribers* to Specialty Pharmacy News can access this Web portal with three years of back issues, searchable article archives and other valuable resources.

Subscribers to Specialty Pharmacy News receive

  • 12 monthly issues packed with news and strategies on this increasingly vital sector in health business, delivered First Class by U.S. Mail and electronically (optional),
  • E-News Alerts whenever important news breaks, and
  • Access to a subscriber-only Web page with:
    • Searchable archives of past articles,
    • Convenient library with PDFs of back issues,
    • Recent stories of interest and hot topic articles grouped for convenient reading, and
    • Regular postings from Managing Editor Angela Maas.
View a sample and get more information
June 2016

Recent Stories

From Specialty Pharmacy News - Although CMS has yet to make an announcement, a spokesperson for the agency confirms that the Oncology Care Model (OCM) will start July 1. The US Oncology Network spoke with SPN about what it’s doing to help prepare practices for the launch. According to the Association of Community Cancer Centers, in March CMS’s Center for Medicare and Medicaid Innovation offered invitations to more than 100 applicants. The CMS spokesperson says the list of participants is not public yet. More than 400 practices and 40 payers submitted letters of intent to participate. Read more

Blue Cross and Blue Shield of New Mexico earlier this year launched… Read more

A dispute between the New York attorney general and various health insurers… Read more

As genetic tests continue to flood the market, Cigna Corp. is preparing… Read more

From the Editor

Welcome to your Specialty Pharmacy News subscriber-only Web page

Be sure to visit often, for PDFs of issues, archives of articles and data, and more!

Please e-mail me with your comments on the last issue of Specialty Pharmacy News, story ideas for future issues, or any other suggestions you have that can make the newsletter more useful for you.

June 7, 2016
Genentech, OSI Settle False Claims Allegations for $67M

Genentech and OSI Pharmaceuticals will pay $67 million to settle false claims allegations on statements the companies made about cancer drug Tarceva.

June 2, 2016
Tarceva Companion Diagnostic Approved

FDA approves Roche’s cobas EGFR Mutation Test v2, a companion diagnostic for Tarceva. Product is the first blood-based genetic test to detect EGFR gene mutations in people with non-small cell lung cancer

May 18, 2016
Genentech Bladder Cancer Drug Gets Accelerated Approval

FDA gives accelerated approval to Genentech’s Tecentriq (atezolizumab) to treat common type of bladder cancer; drug is first and only anti-PDL1 cancer immunotherapy with FDA approval

Updated Regularly

Featured Hot Topics

Search for your own Hot Topics

It's quick and easy to sign up for FREE access to!

Why do I need to register?